These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

881 related items for PubMed ID: 20661914

  • 1. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M, Trastuzumab Response Biomarker Group.
    Cancer; 2010 Nov 15; 116(22):5168-78. PubMed ID: 20661914
    [Abstract] [Full Text] [Related]

  • 2. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.
    Desmedt C, Sperinde J, Piette F, Huang W, Jin X, Tan Y, Durbecq V, Larsimont D, Giuliani R, Chappey C, Buyse M, Winslow J, Piccart M, Sotiriou C, Petropoulos C, Bates M.
    Diagn Mol Pathol; 2009 Mar 15; 18(1):22-9. PubMed ID: 19214112
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.
    Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ.
    Clin Breast Cancer; 2005 Aug 15; 6(3):240-6. PubMed ID: 16137435
    [Abstract] [Full Text] [Related]

  • 4. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
    Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmöller P, Gutjahr T, Kaufmann M, Henkel T, Rüschoff J.
    J Clin Pathol; 2008 Jan 15; 61(1):89-94. PubMed ID: 17412870
    [Abstract] [Full Text] [Related]

  • 5. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
    Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, Huang W, Leitzel K, Weidler J, Ali SM, Fuchs EM, Singer CF, Köstler WJ, Bates M, Parry G, Winslow J, Lipton A.
    Clin Cancer Res; 2010 Aug 15; 16(16):4226-35. PubMed ID: 20664024
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA.
    J Clin Oncol; 2011 Feb 01; 29(4):398-405. PubMed ID: 21172893
    [Abstract] [Full Text] [Related]

  • 7. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM, de Munck L, de Graaf JC, Siesling S, de Vries EG, Boers JE.
    Eur J Cancer; 2014 Mar 01; 50(5):885-91. PubMed ID: 24491395
    [Abstract] [Full Text] [Related]

  • 8. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
    Aoyama K, Kamio T, Nishikawa T, Kameoka S.
    Jpn J Clin Oncol; 2010 Jul 01; 40(7):613-9. PubMed ID: 20202990
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
    Dybdal N, Leiberman G, Anderson S, McCune B, Bajamonde A, Cohen RL, Mass RD, Sanders C, Press MF.
    Breast Cancer Res Treat; 2005 Sep 01; 93(1):3-11. PubMed ID: 16184453
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G.
    Breast Cancer Res Treat; 2011 Jul 01; 128(2):447-56. PubMed ID: 21594665
    [Abstract] [Full Text] [Related]

  • 12. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
    Fabi A, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, Ercolani C, Ferretti G, Melucci E, Buglioni S, Sperduti I, Papaldo P, Cognetti F, Mottolese M.
    Clin Cancer Res; 2011 Apr 01; 17(7):2055-64. PubMed ID: 21307144
    [Abstract] [Full Text] [Related]

  • 13. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, Kostopoulou V, Mylonakis N, Karabelis A, Pectasides M, Economopoulos T.
    Anticancer Res; 2006 Apr 01; 26(1B):647-53. PubMed ID: 16739334
    [Abstract] [Full Text] [Related]

  • 14. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
    Clay MR, Iberri DJ, Bangs CD, Cherry A, Jensen KC.
    Am J Surg Pathol; 2013 Jan 01; 37(1):120-7. PubMed ID: 23108020
    [Abstract] [Full Text] [Related]

  • 15. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    Reddy JC, Reimann JD, Anderson SM, Klein PM.
    Clin Breast Cancer; 2006 Jun 01; 7(2):153-7. PubMed ID: 16800975
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.
    Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P.
    J Clin Oncol; 2005 Apr 01; 23(10):2162-71. PubMed ID: 15800309
    [Abstract] [Full Text] [Related]

  • 17. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.
    Duchnowska R, Sperinde J, Chenna A, Haddad M, Paquet A, Lie Y, Weidler JM, Huang W, Winslow J, Jankowski T, Czartoryska-Arłukowicz B, Wysocki PJ, Foszczyńska-Kłoda M, Radecka B, Litwiniuk MM, Zok J, Wiśniewski M, Zuziak D, Biernat W, Jassem J.
    Clin Cancer Res; 2014 May 15; 20(10):2805-13. PubMed ID: 24668646
    [Abstract] [Full Text] [Related]

  • 18. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
    Arnould L, Arveux P, Couturier J, Gelly-Marty M, Loustalot C, Ettore F, Sagan C, Antoine M, Penault-Llorca F, Vasseur B, Fumoleau P, Coudert BP.
    Clin Cancer Res; 2007 Nov 01; 13(21):6404-9. PubMed ID: 17975153
    [Abstract] [Full Text] [Related]

  • 19. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M.
    Orv Hetil; 2001 Nov 18; 142(46):2563-8. PubMed ID: 11770175
    [Abstract] [Full Text] [Related]

  • 20. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R, Okumura Y, Arima N.
    Breast Cancer; 2008 Nov 18; 15(1):57-64. PubMed ID: 18224396
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.